Editorial: Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer?
In this issue of BJU International, Karzai et al. [1] report the results of a phase I study of the anti-endoglin antibody TRC105 in patients with metastatic castration-resistant prostate cancer (mCRPC). This is a new anti-angiogenic compound with a unique mechanism of action. Since the introduction of the concept of angiogenesis as a requirement for tumour […]